These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 29555460

  • 1. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
    Zhao P, Li M, Wang Y, Chen Y, He C, Zhang X, Yang T, Lu Y, You J, Lee RJ, Xiang G.
    Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
    [Abstract] [Full Text] [Related]

  • 2. MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
    Zhao P, Wu S, Cheng Y, You J, Chen Y, Li M, He C, Zhang X, Yang T, Lu Y, Lee RJ, He X, Xiang G.
    Nanomedicine; 2017 Nov; 13(8):2507-2516. PubMed ID: 28577837
    [Abstract] [Full Text] [Related]

  • 3. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
    Khan MW, Zhao P, Khan A, Raza F, Raza SM, Sarfraz M, Chen Y, Li M, Yang T, Ma X, Xiang G.
    Int J Nanomedicine; 2019 Nov; 14():3753-3771. PubMed ID: 31239661
    [Abstract] [Full Text] [Related]

  • 4. A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
    Li M, Su Y, Zhang F, Chen K, Xu X, Xu L, Zhou J, Wang W.
    Acta Biomater; 2018 Jul 15; 75():413-426. PubMed ID: 29859368
    [Abstract] [Full Text] [Related]

  • 5. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N, Liu W, Li B, Nie H, Liu J, Cheng Y, Wang J, Dong H, Jia L.
    J Exp Clin Cancer Res; 2019 May 31; 38(1):232. PubMed ID: 31151472
    [Abstract] [Full Text] [Related]

  • 6. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S, Sun X.
    Oncotarget; 2015 Oct 06; 6(30):28867-81. PubMed ID: 26311740
    [Abstract] [Full Text] [Related]

  • 7. Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma.
    Gan H, Chen L, Sui X, Wu B, Zou S, Li A, Zhang Y, Liu X, Wang D, Cai S, Liu X, Liang Y, Tang X.
    Mater Sci Eng C Mater Biol Appl; 2018 Oct 01; 91():395-403. PubMed ID: 30033270
    [Abstract] [Full Text] [Related]

  • 8. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
    Gao DY, Lin TsT, Sung YC, Liu YC, Chiang WH, Chang CC, Liu JY, Chen Y.
    Biomaterials; 2015 Oct 01; 67():194-203. PubMed ID: 26218745
    [Abstract] [Full Text] [Related]

  • 9. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
    Bian Y, Guo D.
    Drug Des Devel Ther; 2020 Oct 01; 14():647-659. PubMed ID: 32109990
    [Abstract] [Full Text] [Related]

  • 10. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and sorafenib in nanoparticles.
    Wu B, Li A, Zhang Y, Liu X, Zhou S, Gan H, Cai S, Liang Y, Tang X.
    Expert Opin Drug Deliv; 2020 Apr 01; 17(4):573-587. PubMed ID: 32056461
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Gold nanoparticles-loaded anti-miR221 enhances antitumor effect of sorafenib in hepatocellular carcinoma cells.
    Cai H, Yang Y, Peng F, Liu Y, Fu X, Ji B.
    Int J Med Sci; 2019 Apr 01; 16(12):1541-1548. PubMed ID: 31839741
    [Abstract] [Full Text] [Related]

  • 14. Facile fabrication of a novel hybrid nanoparticles by self-assembling based on pectin-doxorubicin conjugates for hepatocellular carcinoma therapy.
    Ye PJ, Huang C, Yang S, Gao P, Li ZP, Tang SY, Xiang Y, Liu YF, Chen YP, He DX, Yu CY.
    Artif Cells Nanomed Biotechnol; 2018 Apr 01; 46(sup3):S661-S670. PubMed ID: 30307317
    [Abstract] [Full Text] [Related]

  • 15. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
    Zhang J, Wang T, Mu S, Olerile LD, Yu X, Zhang N.
    Nanomedicine (Lond); 2017 Apr 01; 12(8):911-925. PubMed ID: 28339312
    [Abstract] [Full Text] [Related]

  • 16. Delivery of miR-375 and doxorubicin hydrochloride by lipid-coated hollow mesoporous silica nanoparticles to overcome multiple drug resistance in hepatocellular carcinoma.
    Xue H, Yu Z, Liu Y, Yuan W, Yang T, You J, He X, Lee RJ, Li L, Xu C.
    Int J Nanomedicine; 2017 Apr 01; 12():5271-5287. PubMed ID: 28769563
    [Abstract] [Full Text] [Related]

  • 17. Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.
    Wu JY, Wang ZX, Zhang G, Lu X, Qiang GH, Hu W, Ji AL, Wu JH, Jiang CP.
    Int J Nanomedicine; 2018 Apr 01; 13():1265-1280. PubMed ID: 29551896
    [Abstract] [Full Text] [Related]

  • 18. Hybrid membrane camouflaged copper sulfide nanoparticles for photothermal-chemotherapy of hepatocellular carcinoma.
    Ji B, Cai H, Yang Y, Peng F, Song M, Sun K, Yan F, Liu Y.
    Acta Biomater; 2020 Jul 15; 111():363-372. PubMed ID: 32434082
    [Abstract] [Full Text] [Related]

  • 19. Preparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma.
    Liang P, Wu H, Zhang Z, Jiang S, Lv H.
    Int J Pharm; 2020 Jun 15; 583():119375. PubMed ID: 32344021
    [Abstract] [Full Text] [Related]

  • 20. Apolipoprotein E Peptide-Guided Disulfide-Cross-Linked Micelles for Targeted Delivery of Sorafenib to Hepatocellular Carcinoma.
    Li Y, Wei J, Wei Y, Cheng L, Guo B, Meng F, Li F, Zhong Z.
    Biomacromolecules; 2020 Feb 10; 21(2):716-724. PubMed ID: 31809037
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.